Director lunches and ‘excessive’ pay probed in biotech collapse

MELBOURNE: A collapsed biotechnology business ran into financial strife partly because of “excessive” ... read more
Imugene soars 30pc on gastric cancer trial

MELBOURNE: An ASX-listed immuno-oncology biotechnology company is providing fresh hope for gastric cancer ... read more